To be a “Lymphomatoid Papulosis Type E” or not to be? That Is a Question | Author : Yong-Moon Lee | Abstract | Full Text | Abstract :Lymphomatoid papulosis (LyP) Type E is a recently introduced subtype of LyP presenting with escar-like lesions and characterized with angiocentric invasion of dermal blood vessels by CD30 positive atypical lymphocytes resulting necrosis of their walls. Owing to its considerable histologic characteristics such as dense dermal infiltration of CD30 positive large atypical lymphocytes showing high mitotic activity, and angiodestructive invasion, it is challengible to discriminate LyP Type E to aggressive cutanoues lymphomas. |
| Simulation of Interaction of Synchrotron Radiation Emission as A Function of the Beam Energy and Plutonium Nanoparticles Using 3d Finite Element Method (Fem) as an Optothermal Human Cancer Cells, Tiss | Author : Alireza Heidari | Abstract | Full Text | Abstract :In the current study, thermoplasmonic characteristics of Plutonium nanoparticles with spherical, core–shell and rod shapes are investigated. In order to investigate these characteristics, interaction of synchrotron radiation emission as a function of the beam energy and Plutonium nanoparticles were simulated using 3D finite element method. Firstly, absorption and extinction cross sections were calculated. Then, increases in temperature due to synchrotron radiation emission as a function of the beam energy absorption were calculated in Plutonium nanoparticles by solving heat equation. The obtained results show that Plutonium nanorods are more appropriate option for using in optothermal human cancer cells, tissues and tumors treatment method. |
| Complementary and Alternative Treatments for Cancer Prevention and Cure [Part 1] | Author : Abdul Kader Mohiuddin | Abstract | Full Text | Abstract :Many lay people along with some so called “key opinion leaders” have a common slogan “There is no answer for cancer”. Again, mistake delays proper treatment and make situation worse, more often. Compliance is crucial to obtain optimal health outcomes, such as cure or improvement in QoL. Patients may delay treatment or fail to seek care because of high out-of- pocket expenditures. Despite phenomenal development, conventional therapy falls short in cancer management. There are two major hurdles in anticancer drug development: dose-limiting toxic side effects that reduce either drug effectiveness or the QoL of patients and complicated drug development processes that are costly and time consuming. Cancer patients are increasingly seeking out alternative medicine and might be reluctant to disclose its use to their oncology treatment physicians. But there is limited available information on patterns of utilization and efficacy of alternative medicine for patients with cancer. As adjuvant therapy, many traditional medicines shown efficacy against brain, head and neck, skin, breast, liver, pancreas, kidney, bladder, prostate, colon and blood cancers. The literature reviews non-pharmacological interventions used against cancer, published trials, systematic reviews and meta-analyses. |
|
|